We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients.
- Authors
Verpooten, G. A.; Cools, F. J.; van der Planken, M. G.; Bedert, L. C.; Claes, R.; van Gaal, L. F.; de Broe, M. E.
- Abstract
Atherosclerosis and thrombosis, two major causes of morbidity and mortality in renal transplant recipients, share the same clinical risk factors including decreased fibrinolysis and lipid disturbances. In a crosssectional study we have determined parameters of fibrinolysis in control subjects (n=23) and stable renal allograft recipients without cyclosporin CsA (n=10) and with CsA (n=87) in their immunosuppressive treatment. In CsA-treated patients, tissue-type plasminogen activator was moderately increased compared to patients without CsA (8.4±3.3 vs 5.5±2.8 ng/ml). The plasminogen activator inhibitor (PAI) activity in plasma was clearly increased in CsA-treated patients: 14.5±8.8 vs 7.2±3.2 in normal controls and 8.5±2.4 AU/ml in patients without CsA. Total cholesterol and LDL cholesterol levels were higher in CsA-treated patients (256±62 and 169±60 mg/dl) than in patients without CsA (209±45 and 136±44 mg/dl). The two groups did not differ in HDL cholesterol, triglycerides, and lipoprotein(a). Hypercholesterolaemia, obesity, and steroid-induced diabetes could be identified as risk factors for elevated plasma PAI activity in CsA-treated patients. Hypofibrinolysis induced by elevated PAI levels and increased LDL cholesterol may contribute to the increased thrombogenicity and accelerated atherosclerosis observed in cyclosporin-treated patients.
- Publication
Nephrology Dialysis Transplantation, 1996, Vol 11, Issue 2, p347
- ISSN
0931-0509
- Publication type
Article
- DOI
10.1093/oxfordjournals.ndt.a027265